In regards to CAR, neither prior Intozumab exposure nor blinatumomab have been show to effect outcomes, as long as a patient’s leukemia had a prior response and retained CD19 expression [30, 38••, 42, 49]. This evidence concerns the gene CD19 and leukemia.